For HBsAg-positive pregnant people with high viral loads (> 200,000 IU/mL or 5.3 log IU/ml), referral should be made to a tertiary specialist to discuss starting tenofovir at 28–32 weeks gestation to further reduce the risk of perinatal transmission.
The Therapeutic Goods Administration pregnancy categories for hepatitis B therapies reflect the limited human safety data but absence of toxicity for humans; thus, all therapies are classified in category B. For more information see here. Prospective registries have provided significant and reassuring data about tenofovir in pregnancy so its use can be recommended with confidence.
Amniocentesis should be avoided if alternatives are possible.
Pregnant people with a high viral load may start on medication and continue up to 12 weeks postpartum.
There is no evidence that elective caesarean delivery reduces the risk of hepatitis B transmission, and this is not recommended in any obstetrics guidelines.